Department of Surgical Oncology and General Surgery, Key Laboratory of Precision Diagnosis and Treatment of Gastrointestinal Tumors, Ministry of Education, The First Affiliated Hospital of China Medical University, Shenyang, Liaoning Province, 110001, People's Republic of China.
Drug Des Devel Ther. 2021 Jun 9;15:2445-2456. doi: 10.2147/DDDT.S308377. eCollection 2021.
Gastric cancer (GC) is one of the most common cancers globally, threatening global health. The deregulation of the Hippo signaling pathway has been discovered in GC and may be related to cancer development, proliferation, metastasis, and drug resistance. Yes-associated protein (YAP), as a downstream effector of the Hippo signaling pathway and a crucial co-transcription factor in the nucleus, is a promising and vital potential drug target for the treatment of GC. A series of drugs or compounds that inhibit YAP has been developed or confirmed. Therefore, this review will focus on summarizing the drugs and small-molecule inhibitors that have been reported to inhibit YAP and discuss the clinical prospects of YAP inhibitors in GC.
胃癌（GC）是全球最常见的癌症之一，威胁着全球健康。Hippo 信号通路的失调已在 GC 中被发现，可能与癌症的发生、增殖、转移和耐药性有关。Yes 相关蛋白（YAP）作为 Hippo 信号通路的下游效应物和核内关键共转录因子，是治疗 GC 的一个有前途和重要的潜在药物靶点。已经开发或证实了一系列抑制 YAP 的药物或化合物。因此，本综述将重点总结已报道的抑制 YAP 的药物和小分子抑制剂，并讨论 YAP 抑制剂在 GC 中的临床前景。
